Skip to main content

Table 2 Anamnestic and laboratory measurement data of type 2 diabetes patients

From: Lower serum chromogranin B level is associated with type 1 diabetes and with type 2 diabetes patients with intensive conservative insulin treatment

Variable Type 2 diabetes patients [n = 100] Age and sex matched controls [n = 47] p value
Age [years] 63.0 ± 11.6 58.4 ± 14.6 0.0589
Duration of diabetes [years] 13.7 ± 10.3
Chromogranin A [ng/mL] a 57.80 ± 34.74 49.97 ± 22.29 0.1587
Chromogranin B [ng/mL] 99.72 ± 54.79 112.54 ± 61.68 0.1698
HbA1C [%] 7.3 ± 1.2
HbA1C [mmol/mol] 56.0 ± 13.1
White blood cell count [109/L] 7.93 ± 2.08 7.21 ± 1.91 0.0443
Red blood cell count [1012/L] 4.82 ± 0.39 5.01 ± 0.56 0.0389
eGFR [mLmin−1(1.73m2)−1] 83.49 ± 17.84 90.19 ± 13.13 0.0117
Body mass index (BMI) [kg/m2] 31.1 ± 5.8 27.9 ± 5.4 0.0017
Sex (Female / Male) 50: 50 24: 23 1.0000
Hypertension 91 17  < 0.0001
Thyroid disease 16 4 0.3038
Gastroesophageal reflux disease 31 5 0.0074
Antacid therapy 29 3 0.0013
  1. Values are expressed as mean ± standard deviation, unit of anamnestic data is the number of observations
  2. eGFR Estimated glomerular filtration rate, HbA1C Glycated hemoglobin
  3. aExcluding the measurement of study subjects, who had any condition leading to chromogranin A elevation [3, 4, 7]. Remaining number of observations was 64 and 43, respectively